newsfilter
← Latest News
ACCESS Newswire·

Ainos Announces Positive Results from Additional Preclinical Study of Its Low-dose Oral Interferon Formulation Against New Variant Virus - Omicron

VELDONA® formulation showed significant stabilization of physical condition and complete recovery from lung inflammation throughout the course of treatment period. By upregulation of immunomodulatory, Ainos' VELDONA® formulation demonstrates efficacy